---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001743"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:56:35.977636+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TriSalus reports Q4 revenue $13.2M (+60% YoY), FY25 $45.2M (+53%), FY26 guidance $60-62M

## Summary
- Q4 2025 revenue approx $13.2M vs $8.3M year ago, up 60% YoY; full-year revenue approx $45.2M vs $29.4M, up 53% YoY.
- Revenue growth exceeded prior guidance of 50% annual growth for 2025.
- Initial 2026 revenue guidance set at $60M to $62M.
- Year-end cash approx $20.4M, down $2.3M from start of Q4 reflecting investment in growth.

## SEC filing metadata
- accession: 0001628280-26-001743
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000162828026001743/0001628280-26-001743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000162828026001743/tlsi-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001743
- JSON: https://secwatch.observer/filing/0001628280-26-001743.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.